pornmovie
massage porn video
mia khalifa porn movie

Clinical Trials–Making Good News Better

Posted Aug 14, 2018

Written by: Steve Piccoli, Chief Science Officer Pierian Bioscience Recent published results (AACR 2018 and NEJM) from the Merck KEYNOTE-189 trial in non-squamous non-small cell lung cancer (NSCLC) proved to be very exciting in the world of oncology. The study showed that patients treated with pembrolizumab (Keytruda™) plus chemotherapy had significantly longer overall survival (OS) and progression-free survival (PFS) compared with those who received chemotherapy alone, meeting both its primary endpoints. Great news for patients! But, could this be even […]

continue reading

European Biopharmaceutical Enterprises Announces CEO of Vaxeal as new President

Posted Jul 19, 2018

The European Biopharmaceutical Enterprises (EBE) has appointed a new president, Ahmed Bouzidi. Dr Bouzidi has been a board member of EBE since its inception until 2003, re-joining the EBE Board in 2012. Ahmed Bouzidi is the founder and Chief Executive Officer of Vaxeal which is one of the projects being funded by Keyholder. It is great news for Vaxeal and Keyholder that Dr. Bouzidi has been appointed to this position. On his appointment as President, Ahmed Bouzidi said “I would […]

continue reading

Celex Added to Keyholder Projects

Posted Jul 2, 2018

We are pleased to announce that two exciting projects, brought to Keyholder by Longacre Funding Partners, have been approved by the Keyholder investment committee for final due-diligence and verification. These are Vaxeal and Celex. Celex converts cancer from a killer disease, to a chronic disease, by preventing cancer from metastasising and being invasive. This is achieved by blocking the electrical signals from cancer cell to cancer cell that are necessary for the formation and growth of a tumour. The drugs […]

continue reading

Vaxeal Added to Keyholder Projects

Posted Jun 11, 2018

We are pleased to announce that two exciting projects, brought to Keyholder by Longacre Funding Partners, have been approved by the Keyholder investment committee for final due-diligence and verification. These are Vaxeal and Celex. Vaxeal is a second generation immunotherapy treatment based on Survivin and Cyclin B. It is for use in conjunction with front line treatments, to make immunotherapy safer and more effective. This is expected to have lower adverse side effects than current treatments, and effective against many […]

continue reading

Diatech Oncology Limited Report to period ending 31 March 2018

Posted Jun 4, 2018

The work completed during 2016 and 2017 has resulted in a better and more reliable assay than was the case when the IM was published in November 2015. Management are confident that these changes of will lead to a technologically improved product, and to an earlier Liquidity Event than might have occurred under the original program, albeit at the expense of a narrower series cancers which have been tested. The cost to arrive at this result is expected to be […]

continue reading

Progress made towards universal blood test for cancer

Posted Jan 24, 2018

Scientists have taken a step towards one of the biggest goals in medicine – a universal blood test for cancer. A team at Johns Hopkins University has trialled a method that detects eight common forms of the disease. Their vision is an annual test designed to catch cancer early and save lives. Tumours release tiny traces of their mutated DNA and proteins they make into the bloodstream. The CancerSEEK test looks for mutations in 16 genes that regularly arise in […]

continue reading

Diatech Oncology Limited Report to period ending 31 October 2017

Posted Jan 15, 2018

The Information Memorandum was released in November 2015, with first funding taking place in January 2016. Since then although the level of funding has been disappointing, with parent company support, and the support of certain shareholders of the parent company, the Company has been able to continue its research and development at a reasonable rate. During the year it was found that the optical assay which formed the basis of the MiCK development was not performing with the reliability and […]

continue reading

Polyclonal Antibody Stimulator 4th Quarter 2017 Development Update

Posted Jan 15, 2018

The primary focus of Vaccicure in 2017 has been reinitiating manufacturing activities and producing Good Manufacturing Practice (GMP)-compliant batches of PAS for future clinical trials and marketing registration purposes. The first 15-g demonstration test batch utilizing starting materials from the existing inventory was produced as planned in July of 2016. In the third and fourth quarter of 2016 the demonstration batch underwent significant quality and analytical release testing. These tests have been completed and the final batch records and certification […]

continue reading

Former AAA-rated manager to head cancer breakthrough fund

Posted Oct 20, 2017

Former Citywire AAA-rated Ian Lancaster’s Cogent Asset Management has been selected to manage a cancer breakthrough fund that invests in treatments that are in late-stage development. The fund, which is being advised by specialist consultants Keyholder Investments, was launched by Luxembourg-based Luxif Management. The fund manager is targeting between £300 million and £500 million and will be investing in six to eight assets. The fund expects to return an average of between 3% and 10% per annum net of fees, […]

continue reading

Stephen Marsden on Impact Investment panel at the Monaco Family Office Investment Summit

Posted Jun 14, 2017

Keyholder Chairman Stephen Marsden is to contribute to a keynote panel session entitled Impact & Social Responsible Investment Opportunities at the Monaco Family Office Summit on the 15th June. This session will take a look at the nuances of this space, and hear directly from top international family offices. It will address the questions: ‘What do the next generation of impact investors care about?’ And ‘What are the different trends in impact investing?’ Over 150 delegates are expected to attend […]

continue reading

Value Inflection for 2018 with likelihood of early Liquidity Event

Posted Jan 16, 2017

Update 16 January 2017 The DiaTech CEER Information Memorandum was only released in September 2016, therefore, this will not be a lengthy report. The main development over the fall of 2016 has been the justification of the decision to transfer the assay to the Luminex platform from the microarray platform. The Company is pleased to report that the transfer of the assay to the Luminex platform can be done successfully, with 3 out of 4 tests successfully completed, with good […]

continue reading

Improvements in Technology gives increased accuracy

Posted Jan 16, 2017

Report to period ending 31 December 2016 The DiaTech MiCK Information Memorandum was released in November 2015, with first funding taking place in January 2016. Since then, although the level of funding has been disappointing, with parent company support and the support of certain shareholders of the parent company, the Company has been able to continue its research and development at a reasonable rate. In the original embodiment of the MiCK assay, the platform used proprietary technologies that measured optical […]

continue reading

Update from Vaccicure shows Project well on track

Posted Jan 13, 2017

The primary focus of Vaccicure in the third and fourth quarter of 2016 is reinitiating manufacturing activities and producing Good Manufacturing Practice (GMP)-compliant batches of PAS for future trials and for marketing registration purposes. The first 15-g demonstration batch utilizing starting materials from the existing inventory was produced as planned in July of 2016. In the third and fourth quarter the demonstration batch has undergone significant quality and analytical release testing. These tests have been completed and the final batch […]

continue reading

Stephen Marsden of Keyholder Funding Limited appointed Chair of Middle East Family Office Investment Summit

Posted Dec 14, 2016

December 7th 2016, Dubai Stephen Marsden, the Executive Chairman of Keyholder Funding Limited, was appointed the Chair of the Middle East Family Office Investment Summit held in Dubai on 7th and 8th December 2016. Stephen opened the event by addressing the gathered delegates to welcome ambassadors, consuls, Royal Family Members and family office representatives from 25 different countries. In Stephen’s opening address, he gave special thanks to the Al Duaij Family represented by Mohammed Al Duaij and the Ritossa Family […]

continue reading

DiaTech Oncology TPA Limited Launches Information Memorandum

Posted Oct 7, 2016

5th October 2016 marked the launch of the DiaTech Oncology TPA investment opportunity. DiaTech Oncology TPA Limited, the company set up to fund the final trials and commercialisation of the CEER platform developed by Pierian Biosciences, has now produced the final Information Memorandum that was made available to qualifying investors on 5th October. The unique CEER technology was brought to DiaTech from Nestlé in a deal announced on September 20th, 2016. Funding is through the purchase of Redeemable Preference Shares. […]

continue reading

New Directors added to Board of Vaccicure Limited

Posted Oct 7, 2016

Vaccicure Limited has strengthened its board by adding 3 non-executive “Independent” directors, Arthur Fowle, Lee McCracken and Warren Stern. Dr Arthur Fowle FRCP Dr Fowle trained at King’s College Hospital, London, intending to practise cardiology. He joined Wellcome Research Laboratories, Beckenham, in 1965 as a clinical physiologist. Security of tenure was promised if he became a part-time consultant physician in the NHS. In the interval, clinical pharmacology was formally recognized as the discipline which he practised. He became head of […]

continue reading

DiaTech Holdings Licenses CEER® Oncology Platform from Prometheus Laboratories, Builds Cross-Scientific Platform

Posted Sep 21, 2016

DiaTech Holdings, Inc., the premier developer of life science technologies providing treatment directing data to aid physicians in selecting the most appropriate therapy for their patients with cancer, today announced that it has licensed the CEER® Oncology platform from Prometheus Laboratories Inc., a Nestlé Health Science (NHSc) company. The unique CEER immuno-proximity assay configuration delivers industry leading analytical sensitivity and specificity in the identification of potential tumor driver(s) based on a functional proteomic approach, to help guide the selection of […]

continue reading

The need for treatment-directing diagnostics emerges as major theme at 2016 ASCO conference

Posted Jun 7, 2016

This month the Clinical Cancer Advances 2016 report presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, has focused heavily on specific targeting of genomic/proteomic markers of cancer. This has led to much media attention on such projects with articles on the BBC and Daily Mail websites, among others. In fact, data pooled from over 13,000 patients in 346 clinical trials and presented at the conference (Dr. Maria Schwaederle and colleagues, University of California […]

continue reading

Keyholder Sponsors Middle East Investment Summit

Posted Apr 14, 2016

Keyholder Funding Limited is sponsoring the 17th annual Middle East Investment Summit taking place on the 2nd and 3rd May 2016 in Dubai. The Middle East Investment Summit connects investors with financial market gurus and world class fund managers. Dr Ian Ferrier of Sibelius LLC a company engaged by Keyholder will be speaking in the Private Equity Sector Showcase in a section entitled ‘In conversation with leading healthcare investors’ at 2.30pm on day one. He will also be speaking at […]

continue reading

Dubai Investment Presentations 21-24 March 2016

Posted Mar 14, 2016

Keyholder is holding a series of presentations focused on selected investment opportunities directed at the provision of individual patient-directed treatment in oncology. These opportunities are de-risked, asset-based investments in transformative, disruptive, and high return technologies associated with the fight against cancer Key Speakers: Dr. Ian R. Ferrier: a widely recognized authority in the field of Cancer diagnosis and monitoring Prof. Graham A. Ferrier: Former professor of molecular biology and proteomics, UCLA Group Presentations starts – 10.30 – 12.00 Individual presentations […]

continue reading